Other drugs with similar target profiles include pioglitazone, a PPAR-γ agonist that demonstrated improvement in steatosis and lobular inflammation in a phase 3 randomized, placebo-controlled trial of adults with NASH [37]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.